Vivos Therapeutics (VVOS) Competitors $3.20 +0.25 (+8.47%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VVOS vs. MLSS, APYX, NTRB, NXL, CTSO, CLGN, BLAC, COCH, ICAD, and OMShould you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include Milestone Scientific (MLSS), Apyx Medical (APYX), Nutriband (NTRB), Nexalin Technology (NXL), Cytosorbents (CTSO), CollPlant Biotechnologies (CLGN), Bellevue Life Sciences Acquisition (BLAC), Envoy Medical (COCH), iCAD (ICAD), and Outset Medical (OM). These companies are all part of the "medical equipment" industry. Vivos Therapeutics vs. Milestone Scientific Apyx Medical Nutriband Nexalin Technology Cytosorbents CollPlant Biotechnologies Bellevue Life Sciences Acquisition Envoy Medical iCAD Outset Medical Milestone Scientific (NYSE:MLSS) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment. Which has more risk and volatility, MLSS or VVOS? Milestone Scientific has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.71, meaning that its share price is 671% more volatile than the S&P 500. Do insiders and institutionals believe in MLSS or VVOS? 5.8% of Milestone Scientific shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 24.8% of Milestone Scientific shares are owned by company insiders. Comparatively, 3.0% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate MLSS or VVOS? Milestone Scientific presently has a consensus price target of $1.25, indicating a potential upside of 58.43%. Vivos Therapeutics has a consensus price target of $6.30, indicating a potential upside of 96.88%. Given Vivos Therapeutics' higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Milestone Scientific.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Scientific 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Vivos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in MLSS or VVOS? Vivos Therapeutics received 13 more outperform votes than Milestone Scientific when rated by MarketBeat users. Likewise, 57.69% of users gave Vivos Therapeutics an outperform vote while only 2.70% of users gave Milestone Scientific an outperform vote. CompanyUnderperformOutperformMilestone ScientificOutperform Votes22.70%Underperform Votes7297.30% Vivos TherapeuticsOutperform Votes1557.69% Underperform Votes1142.31% Does the media favor MLSS or VVOS? In the previous week, Vivos Therapeutics had 3 more articles in the media than Milestone Scientific. MarketBeat recorded 7 mentions for Vivos Therapeutics and 4 mentions for Milestone Scientific. Milestone Scientific's average media sentiment score of 0.29 beat Vivos Therapeutics' score of 0.04 indicating that Milestone Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Scientific 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vivos Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is MLSS or VVOS more profitable? Milestone Scientific has a net margin of -52.01% compared to Vivos Therapeutics' net margin of -86.19%. Milestone Scientific's return on equity of -60.26% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Milestone Scientific-52.01% -60.26% -40.23% Vivos Therapeutics -86.19%-335.04%-93.58% Which has higher earnings and valuation, MLSS or VVOS? Milestone Scientific has higher earnings, but lower revenue than Vivos Therapeutics. Milestone Scientific is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Scientific$9.83M6.25-$6.93M-$0.07-11.27Vivos Therapeutics$13.80M1.12-$13.58M-$5.68-0.56 SummaryVivos Therapeutics beats Milestone Scientific on 9 of the 17 factors compared between the two stocks. Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VVOS vs. The Competition Export to ExcelMetricVivos TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.49M$4.51B$5.38B$8.84BDividend YieldN/A36.80%5.13%4.09%P/E Ratio-0.5626.00105.0417.81Price / Sales1.1246.931,235.79158.52Price / CashN/A53.5740.3536.29Price / Book2.015.927.086.50Net Income-$13.58M$13.99M$119.58M$226.22M7 Day Performance12.68%3.26%2.25%4.03%1 Month Performance21.21%4.58%-2.34%4.92%1 Year Performance-19.80%47.10%33.95%29.30% Vivos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVOSVivos Therapeutics2.3393 of 5 stars$3.20+8.5%$6.30+96.9%-19.8%$15.49M$13.80M-0.56160Analyst ForecastMLSSMilestone Scientific2.3995 of 5 stars$0.71+4.4%$1.25+76.6%-0.1%$55.15M$9.83M-10.1130Analyst ForecastAPYXApyx Medical1.4212 of 5 stars$1.45+3.6%N/A-37.7%$54.58M$52.35M-1.75270Gap UpNTRBNutriband0.6328 of 5 stars$4.87-2.2%N/A+99.6%$54.11M$2.09M-6.0110NXLNexalin Technology0.7321 of 5 stars$3.90+2.6%$3.00-23.1%+991.4%$50.15M$110,000.00-6.093CTSOCytosorbents1.2414 of 5 stars$0.90-2.2%$2.00+123.2%-25.8%$49.00M$36.35M-2.49186CLGNCollPlant Biotechnologies1.8688 of 5 stars$4.17-1.7%$11.00+164.1%-27.4%$47.69M$10.96M-2.7070Upcoming EarningsBLACBellevue Life Sciences AcquisitionN/A$11.62+0.2%N/A+7.5%$46.88MN/A0.00N/ACOCHEnvoy Medical2.8528 of 5 stars$2.20+2.3%$7.92+259.8%+109.6%$43.12M$320,000.000.0034Analyst RevisionICADiCAD0.5669 of 5 stars$1.54flatN/A+18.5%$40.87M$17.32M-11.8867Analyst UpgradeGap UpOMOutset Medical2.3977 of 5 stars$0.76+4.1%$4.70+518.1%-83.6%$39.95M$130.38M-0.28520 Related Companies and Tools Related Companies Milestone Scientific Competitors Apyx Medical Competitors Nutriband Competitors Nexalin Technology Competitors Cytosorbents Competitors CollPlant Biotechnologies Competitors Bellevue Life Sciences Acquisition Competitors Envoy Medical Competitors iCAD Competitors Outset Medical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VVOS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
